The startup develops antiviral therapies that inhibit viral replication by depriving viruses of essential nutrients, effectively starving them. This approach targets unmet medical needs in the treatment of various viral diseases, providing a novel method for patient care.
Funding
$4.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for the majority of viral infections, especially those affecting the respiratory tract, are limited, leaving a significant unmet medical need. Many common viral infections, such as the common cold, lack effective therapeutic options, particularly for vulnerable populations. The rapid development of resistance to existing antiviral drugs further compounds the challenge.
Solution
G.ST Antivirals is developing broad-spectrum antiviral therapies that target the host cell's metabolism to inhibit viral replication, effectively starving the virus. This innovative approach focuses on disrupting the virus's access to essential nutrients within the host cell, leading to the elimination of viral reproduction. By targeting the host cell rather than the virus itself, G.ST Antivirals' strategy is designed to be less susceptible to resistance development. Their lead product is a proprietary 2-deoxyglucose (2-DG) containing nasal spray, currently in Phase 2 clinical trials, targeting upper respiratory tract infections caused by rhinoviruses and other respiratory pathogens. The company is also evaluating pre-clinical candidates for the prevention and treatment of virus-associated exacerbations in COPD patients and other high-risk groups.
Target Audience
The primary target audience includes individuals suffering from upper respiratory tract infections, particularly those caused by rhinoviruses, as well as vulnerable populations such as COPD patients at risk of virus-associated exacerbations.
Features
- Proprietary antiviral approach targeting host cell metabolism to inhibit viral replication
- Broad-spectrum activity against various respiratory viruses, including rhinoviruses and coronaviruses
- 2-deoxyglucose (2-DG) containing nasal spray formulation for upper respiratory tract infections
- Phase 2 clinical trial evaluating the efficacy of the nasal spray in rhinovirus-infected patients
- Pre-clinical programs focused on preventing and treating virus-associated exacerbations in COPD patients
- Designed to be less susceptible to viral resistance development compared to traditional antivirals